The Best of the SOLACI-SOCIME 2022 Main Arena: Mitral Valve

During the “Mitral Valve” session (on the first day of the SOLACI-SOCIME 2022 Congress), Dr. Ignacio Amat Santos (SPA) delivered a great talk on transcatheter mitral valve replacement (TMVR).

During his presentation, he discussed different scenarios for transcatheter replacement: mitral valve-in-vale, mitral valve-in-ring, mitral valve in MAC, and new devices for non-calcified native valves. 

When analyzing prognosis, the most complex—by far—is Vi-MAC. The safest route is transseptal access, which has shown the lowest mortality (compared with transapical access).  

He also shared his experience, mainly using Tendyne devices, where 93% of patients had trivial residual myocardial infarction at the 2-year follow-up. 

Ignacio Amat Santos

This therapeutic treatment has limitations that resemble those of MitraClip, particularly in patients with severe impairment of ventricular function or severely dilated ventricles. 

Main post-implantation complications were left ventricle outflow tract and prosthesis migration/embolization. To prevent these, prior septal ablation using alcohol or, in certain cases, thought radiation can be performed. This would lead to a modified outflow tract (NelLVOT).

Lastly, Dr. Amat Santos highlighted that TMVR is still in its early stages, and there are plenty of clinical and technical aspects to solve.

Later, Dr. Luis Nombela-Franco (SPA), from San Carlos Hospital in Madrid, discussed mitral regurgitation (MR) transcatheter treatment using edge-to-edge therapy.

According to registries, over 150,000 edge-to-edge devices have been implanted worldwide—mainly MitraClip, although the Pascal P10/Ace is also available. Indications include primary MR (non-surgical patients) backed by the Everest study results, but we are still waiting for the results of the MITRA-HR and Repair-MR to reach better conclusions.

In terms of functional or secondary MR, both American and European (IIa) guidelines favor edge-to-edge treatment. This evidence is moving forward with the 3-year results of the COAPT study.

Furthermore, proper patient selection is necessary to improve results, and more experienced centers with higher volumes could accept more complex anatomies.

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....